7 min read
Updated 2026-06-07
Prior authorization for infusion therapy: a practical guide
Infusion prior authorization is among the most payer-variable work in a practice. The same drug can need very different proof by plan.
Short answer
Infusion prior authorization stalls most often on step therapy, site of care, diagnosis specificity, and reauthorization timing rather than on the core clinical decision alone.
Infusion and specialty-drug therapy sits at the hard end of prior authorization: high cost, step-therapy heavy, and highly variable by payer and plan. The same drug, for the same indication, can require very different documentation depending on who is paying.
Where infusion approvals stall
A handful of issues account for most of the friction.
- Step therapy. Payers often require documented trial and failure of one or more preferred agents first, in a specific order.
- Site of care. Some plans steer infusions away from the hospital outpatient setting, and a request in the wrong setting is denied.
- Diagnosis specificity. Coverage frequently hinges on a precise ICD-10 code tied to an approved indication.
- Reauthorization. Continued therapy needs evidence of response on the payer’s schedule, and a missed window stops the regimen.
A workflow that holds up
The teams that keep infusion approvals run the same loop every time: confirm the current requirement for this drug on this plan, assemble the step-therapy and clinical proof against it, submit, and track the reauthorization date so continued therapy is never interrupted.
The pattern generalizes across oncology, rheumatology, gastroenterology, and neurology. The drugs and codes differ. The discipline is identical.
Where Upstream helps
Upstream tells the team what a payer checks for a given infusion before the submission goes out, prepares the prior-authorization work, and runs it under the team’s approval. The practice gets the outcome, and the reauthorization date does not slip.